STOCK TITAN

Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. Eastern Time. CEO Kevin Gorman will lead the presentation, which will be available via live webcast on the company's website. A replay will be accessible one hour post-event and archived for a month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease. For more information, visit neurocrine.com.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn(*in collaboration with AbbVie)

###

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301200496.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the J.P. Morgan Healthcare Conference?

Neurocrine Biosciences will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. Eastern Time.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman will represent Neurocrine Biosciences at the conference.

Where can I watch the Neurocrine presentation?

The presentation will be available via live webcast on Neurocrine's website at www.neurocrine.com.

Will there be a replay of the Neurocrine presentation?

Yes, a replay will be available approximately one hour after the presentation and archived for about one month.

What is Neurocrine Biosciences focused on?

Neurocrine Biosciences specializes in developing treatments for serious neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences Inc

NASDAQ:NBIX

NBIX Rankings

NBIX Latest News

NBIX Stock Data

13.82B
99.72M
1%
96.03%
4.19%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO